Clinical Development Network Across Global Newsroom Participants Member Login Submit an RFP

Therapeutic Areas · Oncology and Hematology

Advancing Precision Oncology Through Integrated Clinical Development

Oncology trials are among the most scientifically and operationally demanding studies run anywhere, adaptive designs, biomarker-driven enrollment, complex safety monitoring and fragile patient populations. Guosa Life Sciences delivers oncology and hematology programs end-to-end, from first-in-human through global Phase III.

Submit an RFP Discuss Your Program

Home/Therapeutic Areas/Oncology and Hematology

Overview

Integrated Expertise for Oncology and Hematology

Oncology development rarely fails for a single reason. It fails at the handoffs, between the site and the central lab, between the imaging vendor and the data team, between safety reporting and the medical monitor. Our integrated model removes those seams.

Clinical operations, laboratory coordination, biomarker logistics, pharmacovigilance and regulatory strategy work as one accountable team, close to the patients your protocol needs, including populations that conventional site networks rarely reach.

Explore Solutions

Areas of Expertise

Where We Focus

Solid TumorsHematologic MalignanciesImmuno-OncologyTargeted TherapyCell and Gene TherapyPrecision and Biomarker-Driven TrialsRadiopharmaceuticalsSupportive CareBreast CancerLung CancerGastrointestinal CancersProstate and UrologicLeukemia and LymphomaMultiple MyelomaPediatric OncologyCancer Prevention and Screening

Trial Design and Execution

Built for How Oncology Trials Actually Run

Oncology protocols carry design and operational demands that generic clinical operations teams underestimate. These are the ones we plan for from the start.

Early-phase and dose-finding

First-in-human, dose escalation and expansion, 3+3 and Bayesian designs, with the safety review infrastructure and rapid decision cadence these studies require.

Adaptive and platform trials

Seamless Phase I/II, basket and umbrella designs and platform protocols, supported by the data flow and governance adaptive decisions depend on.

Response assessment

RECIST 1.1, iRECIST, Lugano and disease-specific criteria, with imaging coordination, central review and reader consistency across sites.

Endpoint rigor

PFS, OS, ORR, DoR, MRD and PRO endpoints, defined, collected and monitored so the analysis holds up under regulatory scrutiny.

Precision Medicine and Biomarkers

The Laboratory Is Part of the Trial, Not a Vendor

Biomarker-driven enrollment only works if the sample gets to the right lab, intact, on time and the result gets back before the screening window closes. That is a logistics problem as much as a scientific one, and it is where precision oncology trials most often slip.

Because laboratories, depots and cold-chain logistics sit inside our enterprise rather than outside it, biomarker workflows are designed alongside the protocol, not retrofitted to it.

Central and specialty laboratory coordination
Genomic, molecular and companion diagnostic testing
Biospecimen management and chain of custody
Validated cold-chain and sample logistics
Tumor tissue, liquid biopsy and MRD workflows
Screening-window and turnaround management

Specialized Capabilities

Purpose-Built for This Therapeutic Area

Oncology-experienced investigators and research-ready sites
Independent Data Monitoring Committees and safety review
Medical monitoring by oncology-trained physicians
Complex AE, SAE and dose-limiting toxicity management
Imaging coordination and central independent review
Investigational product handling, including hazardous and cytotoxic agents
Patient recruitment and retention in fragile populations
Long-term survival follow-up

Why GLS

Depth Where It Matters

One accountable team across the full lifecycle, with the scientific depth, quality systems and regional reach that oncology and hematology programs demand.

Sponsors get senior oversight rather than call-center triage, sites that are qualified before activation rather than assessed after it and a single point of accountability when a study needs a decision quickly.

Clinical Operations
Regulatory Affairs
Quality Assurance
Laboratory Services
Pharmacovigilance
Data and Biostatistics

The capability

What We Actually Do

We support oncology and hematology programs from first-in-human through registration and post-approval: dose escalation and expansion studies, basket and umbrella designs, biomarker-selected populations, and the tissue and imaging workflows those designs depend on.

Oncology sites are selected on demonstrated capability rather than reputation. What matters is whether a center has the pathology turnaround to meet a screening window, the pharmacy capability to handle cytotoxic and investigational agents, the multidisciplinary team to manage dose-limiting toxicity, and a documented record of enrolling to comparable protocols.

Regulatory considerations

Dose optimization, response assessment and tissue logistics

Regulatory expectations on dose selection have changed. Authorities no longer accept the maximum tolerated dose as a default rationale for the recommended phase II dose, and now expect comparative dose evaluation with pharmacokinetic, pharmacodynamic, safety and preliminary activity data supporting the choice. Programs designed around a single escalation arm increasingly face questions they cannot answer without additional study.

Response assessment carries its own burden. RECIST 1.1 remains the reference standard for solid tumors, with iRECIST where immunotherapy pseudoprogression is plausible and Lugano criteria in lymphoma. Central imaging review is expected where response is the primary endpoint, and the imaging charter, reader training and adjudication process need to exist before first patient rather than being assembled during the study.

How an engagement runs

The Sequence

1. Design and feasibility

Dose strategy, endpoint and assessment criteria, and site capability assessed against the specific protocol rather than general oncology experience.

2. Set-up

Central imaging and pathology workflows, tissue logistics and pharmacy readiness established before activation.

3. Conduct

Enrollment against plan, toxicity management oversight, sample and image flow monitored for turnaround.

4. Readout

Response data reconciled with central review, safety analysis and reporting.

What you receive

Deliverables

A site capability assessment against protocol requirements. An imaging charter with reader training records. Tissue chain-of-custody documentation. Enrollment and toxicity reporting against plan.

Evidence and context

The Research Behind This Work

Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.

The Future of Clinical Trials in Africa The Untapped Advantage

The Ecosystem